Scopio Labs scoops up $50M; Expressable rakes in $15M for digital speech therapy and more fundings

Also: VisuWell scores $10 million for its telehealth tool, and Epicore Biosystems picks up $10 million for its hydration wearable.
By Laura Lovett
02:49 pm
Share

Photo: Kwanchai Lerttanapunyaporn/Getty Images 

Tel Aviv-based startup Scopio Labs landed $50 million in Series C funding for its digital-medical microscopy services. OurCrowd, Aurum Ventures, Mizrahi-Tefahot Bank Invest and Ilex Medical all participated in this round of funding. This news comes roughly two years after the company closed a $16 million Series B funding round.

The company has created hardware and software tools that are able to digitize, quantify and analyze hematology and digital cytology samples, according to the release. The company also designed an artificial intelligence-based clinical decision support platform that is able to analyze digitized images. 

“Deep Learning can analyze hundreds of times more healthcare data from a patient, supporting physician decisions and detecting conditions like cancers, anemias, and bleeding disorders, as well as infections and allergies. But for us it all begins with high-quality digital imaging data,” Scopio cofounder and CEO Itai Hayut said in a statement. 


Virtual speech therapy provider Expressable scored $15 million in a Series A funding round. F-Prime Capital led the round with participation from Lerer Hippeau, NextView Ventures and Amplifyher Ventures. 

The service pairs clients to a licensed and certified speech therapist based on the patient's needs. Patients and families can participate in virtual care sessions. The platform also offers secure therapist texting services, education videos and weekly homework. 

Adults and children can receive care from the platform. The service caters to a number of conditions including language disorders, speech delays, aphasia, stuttering, autism spectrum disorder and other conditions. The Texas-based startup plans to put the money towards building the company's technology and hiring more speech-language pathologists.

"Building a more efficacious speech therapy model requires not only hiring best-in-class clinicians, but also empowering families with tools and education to integrate therapy techniques at home for accelerated progress," Expressable's president and chief clinical officer, Leanne Sherred, said in a statement. "With this new funding and the support of F-Prime and all of our investors, we are well-positioned to help more families experience the life-changing impact that communication has on healthy childhood development."


Virtual care company VisuWell announced a $10 million funding round led by Fulcrum Equity Partners, with participation from Longmeadow Capital, PJC and UltraGroup. 

The company plans to use the new cash to expand its telehealth platform and develop new offerings. The Nashville-based startup plans to grow its white label products. Currently the tool is used for telemedicine, virtual triage, asynchronous visits and bidirectional EHR integrations. 

The company is setting its sights on the urgent care space, with plans to launch a new virtual urgent care product. 

"The explosion in demand for telemedicine has been a catalyst for accelerated growth of virtual care solutions and has sparked a growing need for hospital systems to offer proven digital health platforms to care for all of their patients," Jeff Muir of Fulcrum Equity Partners said in a statement.


Epicore Biosystems, maker of a hydration and metabolic-health wearable, raised $10 million in Series A funding. Chevron Technology Ventures, Alumni Ventures and Joyance Partners participated in this funding round. 

The Northwestern University spinout created a wearable patch and corresponding platform, which uses eccrine sweat to measure hydration, stress, glucose and other personal data. The company has previously teamed up with PepsiCo and Gatorade on a wearable that gives real-time insights on athletes' hydration. 

“Wearable sensor technology to track dehydration and heat stress in field settings provides real-time health and safety metrics for the workforce. Our recent proof-of-concept field study with Epicore Biosystems helped us evaluate the technology and its potential to transform workplace safety,” Barbara Burger, vice president of innovation and president of Technology Ventures for Chevron, said in a statement.

“This is the latest investment in our Core Energy Fund, which focuses on operational enhancement, digitalization and lower carbon business solutions.” 

Share